Anthony G. Quinn
CIK 1532219 · President & CEO · last filed 2026-02-09
Anthony G. Quinn is a President & CEO who has filed 57 SEC Form 4 insider transactions across 4 companies since 2011. The most recent filing, for GBIO, was dated Feb 9, 2026. Across all open-market trades the lifetime net is −$6.5M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
4
57
-$6.48M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Generation Bio Co. (GBIO) Delisted | Director | 0 | $5.34 | $0 | $328.0K | 11 | 2026-02-09 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | President & CEO | 816,835 | $12.01 | $9.81M | $2.20M | 24 | 2022-03-18 |
| Kaleido Biosciences, Inc. (KLDO) Delisted | Director | 31,603 | $0.29 | $9.2K | $0 | 3 | 2021-07-01 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | EVP, CMO, & Head of R&D | 32,675 | — | — | -$9.01M | 19 | 2015-06-23 |
Recent Filings
57 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-09 | Generation Bio Co. (GBIO) Delisted | Mixed | −37,211 | $0 | EDGAR |
| 2025-06-06 | Generation Bio Co. (GBIO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-01-14 | Generation Bio Co. (GBIO) Delisted | Buy (P) | +210,791 | $203.2K | EDGAR |
| 2024-06-10 | Generation Bio Co. (GBIO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-12-05 | Generation Bio Co. (GBIO) Delisted | Buy (P) | +88,495 | $124.8K | EDGAR |
| 2023-06-12 | Generation Bio Co. (GBIO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-13 | Generation Bio Co. (GBIO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-03-18 | Spyre Therapeutics, Inc. (AGLE) Delisted | Buy (P) | +80,079 | $187.7K | EDGAR |
| 2022-03-15 | Spyre Therapeutics, Inc. (AGLE) Delisted | Buy (P) | +144,666 | $280.9K | EDGAR |
| 2022-02-22 | Spyre Therapeutics, Inc. (AGLE) Delisted | Grant (A) | — | $0 | EDGAR |